# Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

> **NCT01894256** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 56 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** Olaparib tablet dosing

## Key facts

- **NCT ID:** NCT01894256
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-03
- **Final completion:** 2016-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894256, "Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01894256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*